$132 Million is the total value of Knoll Capital Management, LLC's 17 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BHVN | Biohaven Pharmactl Hldg Co L | $38,593,000 | +39.2% | 749,815 | 0.0% | 29.33% | -7.0% | |
| ABEO | Abeona Therapeutics Inc | $17,368,000 | +3.1% | 2,359,767 | 0.0% | 13.20% | -31.1% | |
| ALDX | Aldeyra Therapeutics Inc | $4,371,000 | +8.8% | 484,096 | 0.0% | 3.32% | -27.3% | |
| ECOR | Electrocore Inc | $2,778,000 | +11.8% | 396,825 | 0.0% | 2.11% | -25.3% | |
| AVXL | Anavex Life Sciences Corp | $2,209,000 | +95.5% | 724,205 | 0.0% | 1.68% | +30.6% | |
| ENTX | Entera Bio Ltd | $2,057,000 | +41.9% | 475,540 | 0.0% | 1.56% | -5.3% | |
| EIGR | Eiger Biopharmaceuticals Inc | $1,052,000 | +37.7% | 75,238 | 0.0% | 0.80% | -8.1% | |
| SNGX | Soligenix Inc. | $767,000 | +6.4% | 837,800 | 0.0% | 0.58% | -28.9% | |
| MTEM | Molecular Templates | $662,000 | +43.9% | 113,905 | 0.0% | 0.50% | -3.8% | |
| LPCN | Lipocine Inc New | $116,000 | +78.5% | 50,000 | 0.0% | 0.09% | +18.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 38 | Q2 2024 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 29 | Q2 2024 | 79.6% |
| Entera Bio Ltd | 25 | Q2 2024 | 7.8% |
| Applied Therapeutics Inc | 21 | Q2 2024 | 23.6% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Entera Bio Ltd. | January 16, 2024 | 3,881,879 | 10.0% |
| Aldeyra Therapeutics, Inc. | October 04, 2023 | 3,595,916 | 6.1% |
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-03 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.